Pharmaceutical

Aily Labs Expands Board and Advisory Board with AI and Industry Heavyweights to Accelerate Agentic AI Adoption Across the Fortune 500

Aily Labs welcomes Amy Chang, a technology visionary and current board member of Disney and Procter & Gamble, to its…

8 months ago

Cryoport to Report First Quarter 2025 Financial Results on May 7, 2025

NASHVILLE, Tenn., April 24, 2025 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global provider of supply…

8 months ago

Connect Biopharma Announces Multiple Presentations at the American Thoracic Society (ATS) 2025 International Conference

– Data to be presented supports development of rademikibart for patients with moderate-to-severe asthma or COPD experiencing an acute exacerbation…

8 months ago

VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market

SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company”) announced that it has emerged…

8 months ago

X4 Pharmaceuticals to Report First-Quarter 2025 Financial Results and Host Conference Call and Webcast on May 1, 2025

BOSTON, April 24, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people…

8 months ago

Ardelyx Announces Three Abstracts Accepted for Poster Presentations at Digestive Disease Week 2025 Conference

WALTHAM, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to…

8 months ago

NephroDI Therapeutics’ Founder and CMO Jeff M. Sands, M.D. Receives the 2025 Robert W. Berliner Award for Excellence in Renal Physiology

April 25, 2025, Seattle, WA – NephroDI Therapeutics (NephroDI), a pharmaceutical company focusing on kidney disorders, announces that its Founder…

8 months ago

Fulcrum Therapeutics to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 8:00 a.m. ET

CAMBRIDGE, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused…

8 months ago

Collegium to Report First Quarter 2025 Financial Results on May 8, 2025

STOUGHTON, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report first quarter…

8 months ago